ICBP Phase 2 Research

ICBP research icons_large

Our latest journal article

ICBP’s latest cancer survival, incidence and mortality benchmark (1995-2014)

Read the article 

The ICBP has now published the updated international cancer benchmark in Lancet Oncology, describing the cancer survival, incidence and mortality differences across the ICBP jurisdictions.

Further publications from SurvMark-2 are planned, exploring survival by stage for the 8 cancer sites, trends in histology and age disparities. 

Exploratory research to understand the factors contributing to survival differences will be publishing results throughout 2019 and 2020.

The ICBP has now published the updated cancer benchmark, where data on 3.9 million cancer cases was collected from population-based cancer registries in 21 jurisdictions in 7 countries during 1995-2014. Population-based net cancer survival, age-standardised 1 and 5-year survival were all calculated. Changes in survival were then mapped to changes in incidence and mortality rates to establish a holistic understanding of cancer control. 

1-year net survival changes

5-year net survival changes

Key findings

For all cancer sites studied, 1- and 5- year net survival increased in all countries over the 1995-2014 period. The differences internationally in 1-year survival narrowed over time for all cancer sites other than pancreas. This was also true for 5-year survival in oesophageal and rectal cancers only. Greater improvements in survival were seen in patients aged less than 75 years at diagnosis, compared to those aged 75+ years. 

One-year survival estimates were higher for all cancers in Australia, Canada and Norway, followed by Denmark, Ireland, New Zealand and the UK for the most recent 5-year period (2010-2014). This was similar for 5-year survival estimates with higher survival seen in Australia (except for lung in Canada and ovarian in Norway) and lower survival seen in the UK (except for oesophageal in Denmark and ovarian in Ireland).  

By exploring trends in incidence, survival and mortality, progress was seen in cancer control for all countries in stomach, colon, ovarian and lung cancer (in males only). 

International differences in survival continue to exist for those cancers associated with poorer prognosis. Pancreatic cancer has the lowest survival amongst the 7 cancer sites studied, however there were increases in survival in most countries.

Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study (2019)

Differences in access to diagnostics may be contributing to observed international cancer outcomes. Investigating the variation in access to post-diagnosis investigations may provide insights into the extent of efforts to stage and characterise cancers, and the information available to plan treatment. 

Currently the project has been exploring variation in access to PET-CT scanners across the ICBP jurisdictions and expects to have the results of this published later in 2019.

This research is being carried out by the ICBP Programme Management team, based at Cancer Research UK.

High quality care of cancer patients consists of prompt access to the most appropriate and effective treatment – variations within this could partly explain the observed survival differences and impact cancer outcomes internationally.

The ICBP Programme Management team at Cancer Research UK are now conducting research to explore how differences in treatment guidelines, and to what extent they are implemented effectively, could be impacting differences in survival across ICBP jurisdictions.

The first treatments study has focused on variation in ovarian cancer treatment and should be published later in 2019.

During Phase 1 research, it became evident that there may be more subtle differences impacting on cancer survival outcomes regardless of the ICBP partner jurisdictions being otherwise broadly comparable. One element contributing to these subtle differences is the structure of health care systems across the jurisdictions. This research is led by Dr Ellen Nolte at The London School of Hygiene and Tropical Medicine and is focusing on:

  • Identifying features of health systems that might explain observed international differences in cancer survival
  • Understanding the likely influences of high- and medium-level (‘macro’ and ‘meso’) health system factors on the development, implementation and monitoring of pathway use 
  • Working with other ICBP teams to triangulate findings and conclusions

We’ll be updating this section of our webpages as outputs arise.

Most participating jurisdictions have a cancer patient pathway, which sets out how patients should be treated at each stage of their cancer journey. The creation and structure of these were identified in Phase 1 research as a potential contributor to subtle international cancer survival differences. Professor Yoryos Lyratzopoulos at University College London is leading the research into the similarities and differences in the cancer patient pathways across the jurisdictions. The aims of this research module are to:

  • Identify and map routine data sources in each jurisdiction that can support person-level analysis of patient pathways
  • Visualise country-wide pathways for each cancer site using an online data analysis and visualisation tool (currently tested as a method to visualise policy applications for NHS hospitals in England, developed by Health Data Insight CiC) (hyperlink https://healthdatainsight.org.uk/
  • Explore associations between care pathways with health system variables and survival
We’ll be updating this section of our webpages as outputs arise.

Additional Phase 2 Publications

We’re now on twitter.
Join the conversation and follow @CRUKHCPs for news, updates and opinion.

@CRUKHCPs

The University of Manchester are currently conducting a survey into healthcare professionals' and public attitudes towards sun exposure and vitamin D.

Take part

Last reviewed

ICBP Phase 2 Blogs

Measuring up: how does the UK compare internationally on cancer survival?

See more